Fig 1: Targeting association between miR-545-3p and FAM98A. (A-C) The possible targeting relationship between miR-545-3p and FAM98A was predicted through starBase software and verified via dual-luciferase reporter assay. (D, E) FAM98A mRNA and protein levels in ECa tissues (n=35) and matched normal tissues (n=35) were tested via qRT-PCR and Western blot. (F) FAM98A protein level in ECa cells (HEC-1B, EEC and Ishikawa) and hESC cells was measured using Western blot. (G, H) FAM98A protein level was detected by Western blot in HEC-1B and Ishikawa cells transfected with miR-NC, miR-545-3p, anti-miR-NC or anti-miR-545-3p. (I, J) The protein level of FAM98A in HEC-1B and Ishikawa cells transfected with si-circ-IFT80 or/and anti-miR-545-3p was examined by Western blot.circ-IFT80, circular RNA intraflagellar transport 80; ECa, endometrial cancer; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; hESC, human embryonic stem cell; miR-545-3p, microRNA-545-3p; qRT-PCR, quantitative real-time polymerase chain reaction; si-circ-IFT80, circular RNA intraflagellar transport 80 siRNA.*p<0.05.
Fig 2: Circ-IFT80 depletion blocks tumor growth in vivo. (A) After Ishikawa cells containing sh-circ-IFT80 or sh-NC were injected into mice, tumor growth curves were drawn (n=5 per group). (B, C) Following 28 days, xenograft tumors were excised and weighed (n=5 per group). (D, E) The levels of circ-IFT80, miR-545-3p and FAM98A in resected tumors were measured by qRT-PCR and Western blot (n=5 per group). (F) Ki67 positive cells were determined using IHC assay (n=5 per group). (G) Schematic diagram of the molecular mechanism of circ-IFT80/miR-545-3p/FAM98A axis in ECa cell progression.circ-IFT80, circular RNA intraflagellar transport 80; ECa, endometrial cancer; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IHC, immunohistochemistry; miR-545-3p, microRNA-545-3p; qRT-PCR, quantitative real-time polymerase chain reaction.*p<0.05.
Supplier Page from Abcam for Anti-FAM98A antibody